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A Point Mutation in PDGFRB Causes
Autosomal-Dominant Penttinen Syndrome
Jennifer J. Johnston,1,6 Monica Y. Sanchez-Contreras,2,6 Kim M. Keppler-Noreuil,1 Julie Sapp,1
Molly Crenshaw,1 NiCole A. Finch,2 Valerie Cormier-Daire,3 Rosa Rademakers,2 Virginia P. Sybert,4,5,7
and Leslie G. Biesecker1,7,*
Penttinen syndrome is a distinctive disorder characterized by a prematurely aged appearance with lipoatrophy, epidermal and dermal
atrophy along with hypertrophic lesions that resemble scars, thin hair, proptosis, underdeveloped cheekbones, and marked acro-osteol-
ysis. All individuals have been simplex cases. Exome sequencing of an affected individual identified a de novo c.1994T>C p.Val665Ala
variant in PDGFRB, which encodes the platelet-derived growth factor receptor b. Three additional unrelated individuals with this con-
dition were shown to have the identical variant in PDGFRB. Distinct mutations in PDGFRB have been shown to cause infantile myofi-
bromatosis, idiopathic basal ganglia calcification, and an overgrowth disorder with dysmorphic facies and psychosis, none of which
overlaps with the clinical findings in Penttinen syndrome. We evaluated the functional consequence of this causative variant on the
PDGFRB signaling pathway by transfecting mutant and wild-type cDNA into HeLa cells, and transfection showed ligand-independent
constitutive signaling through STAT3 and PLCg. Penttinen syndrome is a clinically distinct genetic condition caused by a PDGFRB gain-
of-function mutation that is associated with a specific and unusual perturbation of receptor function.There is a group of genetic conditions, including Hutch-
inson-Guilford (progeria) syndrome (MIM: 176670),
Wiedemann-Rautenstrauch syndrome (MIM: 264090),
mandibuloacral dysplasia (MIM: 248370),Nestor-Guillermo
syndrome (MIM: 614008), Cockayne syndrome (MIM:
216400), xeroderma pigmentosum groups A–G (MIM:
278700, 610651, 278720, 278730, 278740, 278760,
278780, and 278750), and Werner syndrome (MIM:
277700), with features that resemble premature aging.
Hutchinson-Guilford progeriamanifests in premature death
due toatherosclerosis and renal failure.Otherdisorders, such
as Werner syndrome, Cockayne syndrome, and xeroderma
pigmentosum, primarily cause premature death by cancer
susceptibility and are caused by defective DNA repair. A
numberofdisordershave someattributesofprematureaging
without premature death and are termed ‘‘progeroid’’ disor-
ders. A disorder originally described as a ‘‘new progeroid dis-
order’’ (MIM: 601812) was delineated in 1997 by Penttinen
et al.1 in a child with thin and sparse hair, subcutaneous lip-
oatrophy, sclerotic skin lesions, and acro-osteolysis, among
other features.A subsequent individualwasdescribedbyZuf-
ferey et al.2 We identified two additional individuals with
this distinctive phenotype and performed clinical character-
ization and molecular analysis by exome sequencing and
functional analysisof thealteredprotein. Insight into impor-
tant biological processes canbegainedbyunderstanding the
molecular and pathophysiologic basis of these disorders.
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Individual 1 was originally reported by Penttinen et al.1
He was of Finnish descent, the second child born to
healthy parents, was first seen at 3 years of age, and was
described as having a ‘‘senile’’ appearance, scar-like skin
nodules on the hands and feet, corneal clouding, and a
red reticular rash on his cheeks. Between 6 and 8 years,
he was diagnosed withmild sensorineural hearing loss, hy-
pothyroidism (which his family history is positive for), hy-
peropia, and poor weight gain. At 10 years, he was noted to
have hyperextensible knees and elbows and a ‘‘prema-
turely aged appearance,’’ along with an increase in the dis-
tribution and size of the skin nodules on the hands, feet,
knees, and elbows. Biopsy of a nodule showed deposition
of periodic acid-Schiff (PAS)-stain-negative material in the
dermis. His intelligence was reported to be normal. He
has hadmultiple fractures and scoliosis that required surgi-
cal instrumentation placement, and he receives annual
intravenous zolendonric acid treatment for osteoporosis.
On evaluation at the age of 29 years, his weight was
61.9 kg (10th–25th centile), his height was 174.7 cm (25th
–50th centile), and his occipital frontal circumference
(OFC) was 55.5 cm (45th–50th centile). His anterior fontanel
measured 4.53 3.5 cm and his posterior fontanel measured
53 3 cm. He had sparse, blond hair (Figures 1A and 1B). He
had bitemporal prominences and closely spaced eyes. HeResearch Institute, NIH, Bethesda, MD 20892, USA; 2Department of Neuro-
rtement de Ge´ne´tique, Universite´ Paris Descartes, Sorbonne Paris Cite´ and
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Figure 1. Individual 1 at the Age of 29 Years
(A and B) He had sparse and blond hair, bitemporal prominences,
and closely spaced eyes. He had a long nose with a convex ridge, a
narrow philtrum, and retrognathia.
(C and D) He had severe contractures and shortening of his fingers
and toes with small, broad, and thick toenails. The nodules and
scar-like lesions on the hands, feet, and elbows reported earlier
in life had resolved, although the individual had thin skin with
prominent venous patterning and hyperkeratotic palms and soles
with significant callus formation on the soles.had a long nose with a convex ridge, an extremely narrow
palate and philtrum, and retrognathia. He had partial erup-
tion of four of his maxillary teeth. He had severe contrac-
tures and shortening of his fingers and toes with small,
broad, and thick toenails (Figures 1C and 1D). Ophthal-
mology examination showed bilateral temporal and nasal
corneal edema, occludable anterior segment angles, simple
microphthalmia or nanophthalmos, and retinal striae with
shallow orbits. The nodules and scar-like lesions had
resolved, although he had thin skin with prominent
venous patterning and hyperkeratotic palms and soles,
with significant callus formation on the soles specifically.
Clinical testing showedmoderate to severe sensorineural
hearing loss. A DEXA scan demonstrated severe osteopo-
rosis. His skeletal survey showed thin middle and lower
ribs, bowed and thin tibias, diaphyseal thinning of the
metacarpals and phalanges of the hands, and acro-osteoly-
sis of the hands and feet. Head MRI demonstrated
numerous arachnoid cysts with large cysts in the posterior
fossa; basal ganglia calcifications were not identified on466 The American Journal of Human Genetics 97, 465–474, Septembthis study. Echocardiogram, electrocardiogram, and coro-
nary artery computed tomography (CT) scan were normal.
Individual 2 was originally reported by Zufferey et al.2
She was an adoptee of Northern Vietnamese and Chinese
origin and had features similar to individual 1 that were
evident by three years of age and which progressed over
time. At the age of 8 years, a skin biopsy showed changes
of hyperkeratosis and dermal fibrosis, with discrete areas
of non-specific mononuclear inflammation, resembling
keloid scarring. At age 15 she had a prematurely aged
appearance, thin and sparse hair, atrophic skin with hyper-
trophic scarring on the knees and hands, short fingers, and
flexion contractures of the fingers. Radiographs showed
distal acro-osteolysis of fingers andwormian bones. Similar
to individual 1, she had underdeveloped cheekbones, de-
layed tooth eruption and closure of the fontanels, and
apparently normal intelligence.
Individual 3, the second child born to an Indonesian
mother and Chinese father, was noted at birth to have
macrocephaly. At 16 months of age, a head CT without
contrast showed a cyst in the left posterior fossa. No basal
ganglia calcifications were present. He had moderate
developmental delays and received speech therapy. At
34 months of age, a karyotype, microarray, renal ultra-
sound, and skeletal survey were normal. MRI showed
persistence of the retrocerebellar cyst.
He presented at the age of 7 years with a progressive skin
abnormality reported to have begun at age 2 with several
small smooth, brown bumps on the backs of his hands.
These had increased in number over the years. Height
and weight were both above the 50th centile; his OFC
was 55 cm (95th centile). He responded appropriately to di-
rections, but was almost mute and extremely shy during
the examination.
His facial features (Figure 2A) included frontal bossing,
widely spaced eyes, proptosis with loss of periorbital fat,
and preservation of the buccal fat pads. He had a short
nose, a convex nasal ridge, and underdeveloped cheek-
bones with micrognathia. His teeth were small. He had
short hands and feet, broad and short distal phalanges,
and thickened star-shaped scar-like lesions on the backs
of his hands (Figure 2B), elbows, and knees. His skin was
atrophic in other areas, particularly over his back. There
was a marked vascular pattern evident on his extremities
and on his trunk. His knees and elbows were dispropor-
tionately large.
A skeletal survey showedmacrocephaly with dysplasia of
the mandibular condyles and a small maxilla. The cheek-
bones were underdeveloped with absence of the nasal
bone and nasal spine. There was lucency at the junction of
the right frontal and right parietal bones with overlying
cortical thinning and cortical expansion. The fontanels
were closed. The radii and the ulnae were mildly short.
The distal radius andulnaweregracile anddysplastic bilater-
ally. Therewas acro-osteolysis of all the distal phalanges and
a delayed bone age. His facial features and acro-osteolysis
raised the possibility of mandibuloacral dysplasia, buter 3, 2015
Figure 2. Individual 3 at the Age of 7
Years
(A) He had distinctive facies with thin hair,
sparse eyebrows, widely spaced eyes, long
palpebral fissures, a narrow nasal bridge,
malar flattening, and prognathism. His
skin was thin.
(B) He had broad fingers with short, broad
distal phalanges with hypertrophic scars.sequencing of LMNA (MIM: 150330) and ZMPSTE24 (MIM:
606480) was normal (data not shown).
At the age of 9.5 years, a skin biopsy of a new nodule
showed changes of epidermal atrophy, hyperkeratosis,
and dermal fibrosis. He is currently functioning below
grade level with additional help in all subjects. His teacher
notes that he is withdrawn in class. Formal intellectual
testing was not available.
Individual 4 is of Pakistani descent and was born to
distantly related parents. She presented at six months of
age for ‘‘severe eczema,’’ resulting in hospitalization. At
that time her skin began to darken and poor weight and
linear growth were noted. Her intellectual progress was
reportedly normal. At the age of 4 years the eczema had
resolved, but she had developed ‘‘wart-like’’ growths on
her fingertips. Her weight was at the 10th centile, her
height at the 75th centile, and her OFC was at <2nd centile
(45.4 cm). Her anterior fontanel was open. She had prop-
tosis and closely spaced eyes. Outer canthal and interpupil-
lary measurements were normal. Her nasal ridge was
convex, her maxilla was recessed, and she had microgna-
thia. She had short hands and feet with small distal pha-
langes. There were star-shaped scar-like lesions on her
palms and horizontal linear bands of thickened skin on
the dorsum of her hands and tops of her feet (Figure 3A
and 3B, 6 years of age). Dermatoglyphics were absent,
and there was thickened skin at the ends of the digits.
She had linear areas of thickened skin with pseudopodia
at the elbows and feet. Her skin was dry, but the vascular
pattern was normal. A skeletal survey at age 6 showed a
small maxilla and mandible, acro-osteolysis, thin long
bones, and a small 12th right rib and small cervical ribs.
At 14 years of age, her condition was reported to have
progressed and she was no longer able to walk because of
bleeding of her feet and progression of the skin thickening
(Figure 3D). She had severe contractures of her fingers and
toes (Figure 3C), progressive acro-osteolysis, hyperkeratotic
plaques on her soles, progression of scarring on her elbowsThe American Journal of Human Genand knees, and loss of subcutaneous
tissue in her extremities, giving a
disproportionate, swollen appearance
to her knees and elbows and a marked
venous pattern on her limbs and face,
along with hyperpigmentation. Her
facial features had become more strik-
ing with proptosis, loss of subcutane-
ous tissue, and thinning of her hair.
Her intellect was described as normal or above average,
but no formal testing was available. She was fluent in En-
glish and Urdu. In all four probands, the family history
was negative for other affected relatives.
To identify the causative variant in individual 3, exome
sequencing was performed on genomic DNA isolated
from him and his parents (PureGene). Solution-hybridiza-
tion exome capture was performed with the Illumina Tru-
Seq system and exome sequencing was performed with
the HiSeq 2000 sequencer (Illumina). Image analyses and
base calling were performed as described.3 Reads were
aligned to the NCBI Genome browser reference genome
GRCh37, hg19 with Novoalign (Novocraft Technologies).
Samples were sequenced to sufficient coverage such that
at least 85% of the targeted exome was called with high-
quality variant detection (reported as genotype at every
callable position). Genotypes were called with only those
sequence bases with Phred base qualities of at least Q20
via Most Probable Genotype3 (MPG) and an MPG score of
R10. Filters were applied with the VarSifter Next-Gen
variant analysis software.4 On the basis of the individuals
described above, we used an autosomal-dominant mode
of inheritance and the de novo trio model as the primary
filter. Exome sequencing identified nine protein-coding
variants that conformed to the de novo trio model
and had adequate quality scores. A single variant,
g.149503842A>G (c.1994T>C; p.Val665Ala [GenBank:
NM_002609.3]) on chromosome 5 in PDGFRB (MIM:
173410), was absent in the CLINSEQ cohort of 951 indi-
viduals and was confirmed to be de novo via Sanger
sequencing in both parents. The biologic parentage of
the child was apparent from numerous Mendelian consis-
tencies in the trio data. We then sequenced individuals 1,
2, and 4 for this variant and identified the same mutation
in all three. To control for cross contamination, samples
were tested individually as they were received in the lab,
and negative controls were run with all samples. RT-PCR
using primers spanning introns on total RNA isolatedetics 97, 465–474, September 3, 2015 467
Figure 3. Individual 4 at the Ages of 6
and 14 Years
She is 6 years of age in (A) and (B) and 14
years of age in (C) and (D). The views of
her limbs at these two time points illus-
trate the severity of the progression in
this individual. She had short hands and
feet with small distal phalanges. There
were star-shaped scar-like lesions on her
palms and horizontal linear bands of thick-
ened skin on the dorsum of her hands and
tops of her feet. Dermatoglyphics were ab-
sent, and there was thickened skin at the
ends of the digits. She had linear areas of
thickened skin and pseudopodia of the
feet. Her skin was dry, thickened, and hy-
perkeratotic, but the vascular pattern was
normal.from cell lines from individuals 1 and 3 also showed evi-
dence of the mutation (RNeasy, One-Step RT-PCR,
QIAGEN). In addition, the variant was not detected in
either parent of individual 4, consistent with de novo
occurrence. Parental samples for individuals 1 and 2
were not available. This variant was absent in the NHLBI
Exome Sequencing Project dataset of 6,500 individuals
and in the 61,000-sample Exome Aggregation Consortium
Browser, both accessed November, 2014. We critically eval-
uated these genetic data5 by estimating the statistical sig-
nificance of finding the same de novo nucleotide variant
in two families by chance alone. Using the three-base-
context mutation-rate-prediction approach,6 we estimate
the chance of identifying this same variant in two de
novo occurrences to be on the order of 1016, which is
many orders of magnitude beyond genome-wide signifi-
cance. That the same variant was also identified in two
additional individuals (though parental samples were not
available in these) would further decrease the likelihood
of the null hypothesis. We conclude that these molecular468 The American Journal of Human Genetics 97, 465–474, September 3, 2015genetic findings are statistically sig-
nificant at a genome-wide level.5
We went on to functionally eval-
uate the predicted protein alteration
in the PDGFRB product. We compared
the function of the p.Val665Ala Pent-
tinen syndrome variant to a loss-of-
function p.Leu658Pro variant identi-
fied in individuals with idiopathic
basal ganglia calcification, type 4
(IBGC4 [MIM: 615007])7 and to
wild-type PDGFRB. Human PDGFRB
cDNA c.1973T>C (p.Leu658Pro) and
wild-type pCMV constructs have
been described previously.7 The
c.1994T>C (p.Val665Ala) mutation
identified here was introduced inde-
pendently into the wild-type PDGFRB
pCMV construct with the Quick-
Change Site-Directed Mutagenesis Kit (Stratagene) and
mutagenesis primers (50-CACCTGAACGTGGcCAACCTGT
TGGG-30 [forward] and 50-CCCAACAGGTTGgCCACGTT
CAGGTG-30 [reverse], mutation indicated in lowercase).
We transfected each of the mutant and the wild-type con-
structs into HeLa cells. Cell culture, vector transfection,
and western blotting were performed as described.7 As
expected, the wild-type construct generated three pro-
teins detectable by an anti-PDGFRB antibody (clone
28E1, Cell Signaling Technology) and of approximately
180 kDa, 160 kDa, and 130 kDa, representing the mature,
transmembrane form of the protein and two incom-
pletely post-translationally processed forms, respectively8
(Figure 4A, Table S1). Total PDGFRB was calculated by
adding the intensity of ~180, ~160, and ~130 kDa bands.
Values were normalized to a-tubulin (TUBA1A, clone
DM1A; Sigma-Aldrich) to correct for loading. The
130 kDa form of the protein is minor and is not further dis-
cussed. By comparing the amount of PDGFRB that was pro-
duced by the p.Val665Ala construct to that produced by
Figure 4. Expression of Total PDGFRB
Receptor in HeLa Cells Transfected with
WT, p.Leu658Pro, and p.Val665Ala
PDGFRB Constructs
Representative western blots showing total
PDGFRB (A), phosphorylated PDGFRB at
tyrosine 751 (p-Tyr751) (B), and tyrosine
1021 (p-Tyr1021) (C) of the WT (wild-
type), p.Leu658Pro, and p.Val665Ala vari-
ants. a-tubulin is shown as a protein
loading control (D). Horizontal bars indi-
cate the electrophoretic mobility of three
mature forms of PDGFRB (180, 160, and
130 kDa) (E). Quantitative analysis of the
three mature forms of total PDGFRB was
observed by western blot (n ¼ 3). Values
represent the percentage (average 5
S.E.M.) of each PDGFRB form from the to-
tal PDGFRB in WT cells. *** ¼ p < 0.001,
**** ¼ p < 0.0001. ns, non-significant.the wild-type construct, we observed that the p.Val665Ala
construct generated reduced amounts of total PDGFRB
with somewhat reduced absolute amounts of the
160 kDa species and very little of the mature 180 kDa
form of the protein (Figures 4A and 4E). Co-transfection
experiments with pEGFP-N1 (Clontech Laboratories)
showed a decrease in both EGFP (anti-GFP [MAB3580];
Chemicon International) and PDGFRB in cells transfected
with the p.Val665Ala construct as compared to those
transfected with the wild-type PDGFRB construct (Figures
S1A–S1D, n ¼ 2). Real-time qPCR with gene-expression
probes for PDGFRB (Hs01019589_m1) and GAPDH
(Hs00266705_g1; LifeTechnologies) confirmed these re-
sults, showing reduced expression of PDGFRB in cells
transfected with the p.Val665Ala construct as compared
to cells transfected with the wild-type construct; mRNA
was reduced by 28%, p ¼ 0.0007 (Figure S1E). We are skep-
tical of the hypothesis that the single-nucleotide change in
the construct could lead to this large of a decrease in tran-
scription. More likely is that cells expressing high amounts
of p.Val665Ala PDGFRB have reduced survival, which
would result in lower apparent average total protein
amounts from the transfected vectors. The phenotype
demonstrated in Penttinen syndrome includes acro-osteol-
ysis, osteoporosis, and thin skin, which is consistent
with decreased cell survival. Further experiments are
required to investigate this potential effect of the altered
protein.
In spite of the lower overall amount of transcription
associated with lower protein amounts, the p.Val665Ala
Penttinen variant showed robust ligand-independent auto-
phosphorylation whenwe used antibodies to Tyrosine-751
and Tyrosine-1021 (Figures 4B and 4C) in comparison to
that shown by either the wild-type PDGFRB or the
p.Leu658Pro IBGC variant (phospho-PDGFRb [Tyr1021]
[6F10] and phospho-PDGFRb [Tyr751] [C63G6]; Cell
Signaling Technology). We evaluated the responsiveness
of the wild-type and p.Val665Ala Penttinen syndrome re-
ceptors by using transfected HeLa cells and an exogenousThe AmericanPDGF-BB dimer ligand (one of the natural ligands of this
receptor), confirming that the p.Val665Ala construct pro-
duced greatly reduced amounts of mature 180 kDa isoform
(Figure 5A). Additionally, phosphorylation of both the
Tyrosine-751 and Tyrosine-1021 moieties of the 160 kDa
form of the protein was greatly increased in comparison
to phosphorylation in the wild-type form (Figures 5B–5D
and Table S2). It was evident that the 160 kDa form of
the protein was phosphorylated at both of these tyrosine
residues irrespective of the presence of PDGF-BB ligand,
suggesting a gain-of-function, ligand-independent hy-
persensitivity consequence of this mutation. Signaling
through downstream effector molecules was assessed
with appropriate antibodies (AKT, phospho-AKT [S473]
[193H12], PLCg1 [D9H10] XP, phospho-PLCg1 [Tyr783]
[D6M9S], SRC, phospho-SRC [pY416], phospho-Stat3
[Tyr705] [D3A7] XP, STAT3 [D3Z2G], phospho-ERK1/2
[Thr202/Tyr204] [D13.14.4E] XP, and ERK1/2 p44/42
MAPK; Cell Signaling Technology). The hyper-responsive
phosphorylation of p.Val665Ala PDGFRB did not appear
to be transduced via AKT, a known effector of PDGFRB
signaling,9 given that phosphorylated AKT (pAKT) was
not detectably elevated in the cells transfected with the
mutant construct (Figure 6A and Table S2). Because we did
not see evidenceof increased signal transduction fromp.Va-
l665Ala PDGFRBvia pAKT,wewent on to characterize other
potential mediators of this signal. We surveyed a number
of known mediators of this pathway, including STAT3,
PLCg1, SRC, and ERK, that have been previously found to
beactivatedby thePDGFRBpathway.10Of theseputative ef-
fectors, we saw evidence that both STAT3 and PLCg1 were
phosphorylated by p.Val665Ala PDGFRB in the absence of
PDGF-BB (time point 0 min in Figures 6B and 6C), whereas
neither SRC nor ERK showed evidence of increased signal
transductionas compared that in thewild-typeprotein (Fig-
ures 6D and 6E).
We attempted to study the signaling attributes of this
pathway in primary fibroblasts grown from skin biopsies
from individuals 1 and 3. Cells were passaged in DMEMJournal of Human Genetics 97, 465–474, September 3, 2015 469
Figure 5. Time Course for the Phosphor-
ylation of WT and p.Val665Ala PDGFRB
Receptors
Representative western blots of transfected
HeLa cells treated with PDGF-BB at 5, 15,
30, and 60 min and blotted to detect total
PDGFRB (A), phosphorylated PDGFRB at
tyrosine 751 (p-Tyr751) (B), and tyrosine
1021 (p-Tyr1021) (C). Horizontal bars indi-
cate the electrophoretic mobility of the
two main PDGFRB forms (180 and
160 kDa) (D). Schematic representation
of the quantitative data obtained by west-
ern blot of the time-dependent change in
the PDGF-BB-induced phosphorylation of
PDGFRB (n ¼ 3). Data are expressed as
the fold change (average 5 SEM) in
p-Tyr751 and p-Tyr1021 immunoreac-
tivity at 180 and 160 kDa bands compared
to the corresponding band of total
PDGFRB. * ¼ p < 0.05, ** ¼ p < 0.01,
*** ¼ p < 0.001, **** ¼ p < 0.0001.with 10% fetal bovine serum, 1% penicillin-streptomycin,
13 L-glutamine, and 23 fungizone. For stimulation exper-
iments, cells were grown to 70% confluence in 6 cm dishes
and were serum starved for 24 hr. PDGF-BB ligand (PrePro-
tech) was added at 30 ng/ml, and cells were harvested for
protein. Cells were lysed by a 10 min incubation in
200 ul of 13 cell lysis buffer (eBioscience) with the addi-
tion of enhancer solution (eBioscience), and proteins
were separated on 8%–16% Tris-Glycine gels (Life Technol-
ogies). Proteins were transferred to nitrocellulose (iBlot sys-
tem, Life Technologies). An additional antibody directed
against phospho-PDGFRB (Tyr751) (88H8) was used for
these experiments (Cell Signaling Technology).
We did not see evidence of phosphorylation of the
160 kDa form of the receptor in either of these cell lines,
and there was no evidence of phosphorylation without
ligand stimulation (data not shown). Ligand-induced
phosphorylation of the 180 kDa form of the receptor was
seen in both mutant and control fibroblasts. No apparent
difference was noted between control and mutant fibro-
blasts in either the absolute amount of PDGFRB or the
phosphorylation of the 180 kDa form of the receptor.
Expression of the mutant allele was confirmed by RT-PCR
followed by Sanger sequencing. It is possible that either470 The American Journal of Human Genetics 97, 465–474, September 3, 2015phosphorylation of this form of the
receptor is at amounts too low to be
detected by this assay or the receptor
is degraded or unstable when pro-
duced at natural (as opposed to over-
production in transient transfection
models) amounts in the heterozygous
state. Alternatively, it is possible that
skin fibroblasts are not the appro-
priate cell type for studying the effect
of this PDGFRB mutation. Immuno-
histochemistry may allow differences
to be seen in cells other than fibroblasts, and future studies
are planned to address this question.
PDGFRB (the platelet-derived growth factor receptor b) is
a homodimeric type-III tyrosine-kinase receptor that binds
several ligands, but the physiologically relevant ligand for
this receptor is thePDGF-BBhomodimer. This ligand-recep-
tor pair is involved in processes of wound healing, sclerotic
diseases, and tumor angiogenesis, among others.9,11,12 Mu-
tations inPDGFRBhavepreviously been implicated in three
distinct disorders. Loss-of-function mutations in PDGFRB
cause IBGC4.7,13,14 Predicted gain-of-function mutations
have been associated with autosomal-dominant infantile
myofibromatosis (MIM: 228550),15,16 which has no over-
lapping features with IBGC4. Recently, Takenouchi et al.17
described two individuals with a distinctive phenotype of
skeletal overgrowth, dysmorphic features, and neuro-
behavioral manifestations caused by a recurrent, appar-
ently de novo c.1751C>Gp.Pro584Arg variant in PDGFRB.
We conclude that Penttinen syndrome is allelic to IBGC4,
infantile myofibromatosis, and the syndrome described
by Takenouchi et al.17
The four individuals described here had proptosis, a
convex nasal bridge, underdeveloped cheekbones, de-
layed closure of the fontanels, delayed tooth eruption,
Figure 6. Time Course for the Phosphorylation of PDGFRB Downstream Signaling Molecules in HeLa Cells Transfected with WT and
p.Val665Ala Constructs
Representative western blots of transfected HeLa cells treated with PDGF-BB at 5, 15, 30 and 60 min blotted to detect phosphorylated
AKT (pAKT) and total AKT (A), phosphorylated STAT3 (pSTAT3) and total STAT3 (B), phosphorylated PLCg1 (pPLCg1) and total PLCg1
(C), phosphorylated SRC (pSRC) and total SRC (D), and phosphorylated ERK (pERK) and total ERK (E). a-tubulin is shown as a protein
loading control (F). Molecular size is indicated in kDa. A schematic representation of the quantitative data obtained by western blot of
the time-dependent change in the PDGF-BB-induced phosphorylation of AKT, STAT3, PLCg1, SRC, and ERK is shown at the right of the
corresponding blots (n ¼ 3). Data are expressed as the fold change (average5 SEM) in pAKT, pSTAT3, pPLCg1, pSRC, and pERK in com-
parison to total AKT, STAT3, PLCg, SRC, and ERK, respectively. * ¼ p < 0.05, ** ¼ p < 0.01.progressive cutaneous atrophy and hypertrophic skin le-
sions, and skeletal changes, including acro-osteolysis (Ta-
ble 1). It is striking to us that the hypertrophic skin changes
in the four individuals described here are notmyofibromas;
that, although there are CNS findings in these individuals,
they do not include basal ganglia calcifications; and that,
whereas the individuals described by Takenouchi et al.17
were described as having thin and fragile skin, their facial
features, skeletal changes, and cognitive-psychiatric fea-
tures were distinct from the individuals described here.
These four conditions show very little phenotypic overlap
with each other, and we conclude that the disorder mani-
fested in the four individuals described here is distinct
and should be called Penttinen syndrome.
There are little genetic or functional data upon which to
develop models of pathogenesis that explain the pheno-
type heterogeneity of these four PDGFRB-related disorders.The AmericanThe mutational spectrum of the four disorders is limited to
eight amino acid substitutions (Figure S2). All lie in the car-
boxy-terminal half of the predicted protein,which includes
the kinase domain. We were unable to discern any pattern
or relationship of mutation position to phenotype. Pub-
lished data on the functional consequences of PDGFRB var-
iants are only available for some of the variants associated
with IBGC4. It has been proposed that the PDGFRB variants
associated with infantile myofibromatosis are activating,
based on bioinformatic modeling.16 Indeed, some prelimi-
nary evidence to this effect has been presented (Drs. K.
Oishi, B.R. Evans, and J.A. Martignetti, personal communi-
cation). We are unaware of any published functional data
for the mutation associated with the syndrome described
by Takenouchi et al.17 Several PDGFRB mutations associ-
ated with IBGC4 have been shown to cause a reduction
in the mature, transmembrane form of PDGFRB and aJournal of Human Genetics 97, 465–474, September 3, 2015 471
Table 1. Major Clinical Findings in Four Individuals with Penttinen Syndrome as Compared to Clinical Findings in Three Distinct Disorders
Caused by Mutations in PDGFRB
Age (at last
evaluation)
Individual 1
(Penttinen
et al., 1997)
Individual 2
(Zufferey
et al., 2013) Individual 3 Individual 4
Penttinen
Syndrome
Kosaki
Syndrome
(Takenouchi
et al., 2015)
Infantile
Myofibromatosis
Idiopathic
Basal
Ganglia
Calcification
29 years 15 years 7 years 14 years NA
14 years,
17 yearsa NA NA
Craniofacial
Open fontanelles þ þ  þ þ   
Shallow orbits þ þ þ þ þ   
Narrow nose þ  þ þ þ   
Underdeveloped
cheekbones
þ þ þ þ þ   
Delayed eruption
of teeth
þ þ þ þ þ NS  
Ophthalmologic
Microphthalmia þ NS NS NS þ (?) NS  
Corneal abnorm þ NS NS NS þ (?) NS  
Dermatologic
Thin, translucent
skin with
prominent venous
patterning
þ þ þ þ þ þ  
Lipoatrophy þ þ þ þ þ   
Hyperkeratotic
lesions
þ þ þ þ þ   
Sparse hair þ þ þ þ þ   
Skeletal
Acro-osteolysis þ þ þ þ þ   
Short fingers þ þ þ þ þ   
Contractures þ (fingers,
toes)
þ (fingers) þ (fingers) þ (fingers) þ (fingers,
toes)
  
Osteopenia þ þ þ þ þ   
Thin bones þ þ þ þ þ   
Scoliosis þ    /þ þ  
Skull thin
calvarium
wormian
bones
thin
calvarium
thin
calvarium
thin
calvarium
diffuse
granular
pattern
 
Neurological
Cognitive ability Nl Nl DD NI NI NI, DD NI Abnl
Hearing loss B SNHL     NA  
Brain
malformation
mega
cisterna
magna,
other
cortical and
cerebellar
atrophy
posterior
fossa cyst
NA þ/ extensive
periventricular
white matter
lesions
 basal ganglia
calcifications
Other
Thyroid abnorm hypothyroid NS NS NS þ (?) NS  
Hyperextensible þ þ þ þ þ   
(Continued on next page)
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Table 1. Continued
Age (at last
evaluation)
Individual 1
(Penttinen
et al., 1997)
Individual 2
(Zufferey
et al., 2013) Individual 3 Individual 4
Penttinen
Syndrome
Kosaki
Syndrome
(Takenouchi
et al., 2015)
Infantile
Myofibromatosis
Idiopathic
Basal
Ganglia
Calcification
29 years 15 years 7 years 14 years NA
14 years,
17 yearsa NA NA
Distinguishing Features of PDGFRB Disorders Other than Penttinen Syndrome
Overgrowth      þ  
Myofibromas      þ þ 
Basal ganglia calcifications        þ
Abbreviations are as follows: þ, positive for; , negative for; Abnl, abnormal intelligence; NI, normal intelligence; DD, developmental delay; NA, not applicable;
NS, not assessed; B SNHL, bilateral sensorineural hearing loss; (?), not enough information to be certain.
aOnly two individuals have been described with this condition and these are their ages.reductionof signal transduction via phosphorylation of the
two well-studied tyrosine moieties of this protein.7,10 It is
reasonable to conclude that IBGC4 is caused by a reduced
signal-transduction capacity of this protein.
To understand the distinct clinical consequences of the
Penttinen syndrome mutation, we performed a functional
analysis of this variant and compared it to the p.Leu658Pro
variant that causes IBGC4. We have shown that the Pentti-
nen syndrome variant shows a gain of function through
phosphorylation of tyrosine residues on the 160 kDa form
in the absence of ligand. We conclude from these data that
the Penttinen syndrome variant is a gain-of-function muta-
tion leadingtoexcess, ligand-independentphosphorylation.
Both Penttinen syndrome and myofibromatosis appear
to be caused by gain-of-function mutations. There are a
substantial number of downstream effectors of signal trans-
duction from receptor tyrosine kinases. We show evidence
that the effectors of the p.Val665Ala PDGFRB Penttinen
syndrome variant appear to include STAT3 and PLCg1.
Although mutations in PLCG1 have not been associated
with disease, activating mutations in STAT3 are known to
be involved in cancer and autoimmune disease. Addition-
ally, STAT3 is thought to have a role in keloid formation
given that inhibitors of STAT3 phosphorylation in keloid fi-
broblasts suppress increased collagen production, prolifera-
tion, andmigration.18 The individuals presented here have
hypertrophic skin lesions, and it is possible that activation
of STAT3 plays a role in these lesions. However, further
studies are needed to confirm the involvement of these
two effectors in the etiology of Penttinen syndrome.Wehy-
pothesize that distinct gain-of-function mutations in
PDGFRB transduce aberrant signals throughother effectors,
or combinations of effectors, that are responsible for the
heterogeneous phenotypes associated with mutations in
this gene. Given the currently restricted spectrum of muta-
tions in PDGFRB, we predict that therewill be other distinct
phenotypes associated with mutations in this gene, that
these mutations will be associated with heterogeneous
signal-transduction effects, and that these disorders have
much to teach us about normal and abnormal signal trans-The Americanduction ingrowth, development, andmanyother processes
of health and disease. These data provide hints about ther-
apeutic approaches that may be used to treat disorders
caused by PDGFRB mutations. For Penttinen syndrome,
drugs that inhibit PDGFRB or the downstream effectors
are rational therapeutic candidates.Supplemental Data
Supplemental Data include two tables and two figures and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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